G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis
Tóm tắt
In this retrospective, uncontrolled, observational study, the effect of granulocyte colony-stimulating factor (G-CSF)-stimulated granulocyte transfusions (GTX) in neutropenic paediatric patients with sepsis was evaluated. Granulocytes were collected from unrelated, ABO group-matched and cytomegalic-antibody compatible donors. For neutrophil mobilization, donors received a single subcutaneous dose of glycosylated G-CSF (Lenograstim, Chugai Pharma, Japan) plus oral dexamethasone (8 mg). In total, 168 (range 1–19 per patient) GTX were transfused in 32 children with a median age of 7.4 (0.25 to 16) years. The underlying diseases comprised predominantly haematooncological malignancies (31 children). In 15 of 32 patients, neutropenia was related to allogeneic stem cell transplantation. All children suffered from sepsis based on international criteria (fever, tachycardia, respiratory rate >2 SD above normal in the context of a suspected or proven infection). In ten children bacteria were isolated, in six children a fungal infection was diagnosed and four sepsis episodes were caused by viral infections. GTX contained a median neutrophil number of 6.3 (range 1.9–13.9)×1010 per transfusion and obtained a sustained haematological response after GTX. Nineteen out of 32 children survived the neutropenic sepsis, particularly nine out of 11 patients with bacterial sepsis. In contrast to the non-survivors, we observed a significant decrease in the C-reactive protein levels shortly after initiation of the GTX treatment in the surviving patients. A clear-cut benefit of GTX for children with neutropenic sepsis cannot be concluded from these data, but in children with (severe) bacterial sepsis refractory to antibiotic treatment, GTX were feasible, safe and could reduce mortality rates in this subgroup of patients.
Tài liệu tham khảo
Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP (1994) Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 34:226–232
Bindl L, Nicolai T (2005) Management of septic shock and acquired respiratory distress syndrome in pediatric cancer patients. Klin Padiatr 217(Suppl 1):S130–S142
Briones MA, Josephson CD, Hillyer CD (2003) Granulocyte transfusion: revisited. Curr Hematol Rep 2:522–527
Catalano L, Fontana R, Scarpato N, Picardi M, Rocco S, Rotoli B (1997) Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica 82:71–72
Cesaro S, Chinello P, De Silvestro G, Marson P, Picco G, Varotto S, Pittalis S, Zanesco L (2003) Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer 11:101–106
Goldstein B, Giroir B, Randolph A (2005) International consensus conference on pediatric sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6(1):2–8
Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K (2002) Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection 30:267–271
Haase R, Mathony U, Lieser U, Nagel F, Sitka U, Burdach S (2003) Oncology patients in a pediatric intensive care unit—a 7-year experience. Klin Padiatr 215(4):234–240
Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M (1997) A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580–588
Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O’Brien S, Freireich EJ (1995) Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 10:188–193
Heuft HG, Goudeva L, Pulver N, Grigull L, Schwella N, Blasczyk R (2005) A dose–response analysis of lenograstim plus dexamethasone for neutrophil mobilization and collection. Transfusion 45(4):604–612
Hübel K, Engert A (2003) Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy. Onkologie 26:73–79
Jacobe SJ, Hassan A, Veys P, Mok Q (2003) Outcome of children requiring admission to an intensive care unit after bone marrow transplantation. Crit Care Med 31(5):1299–1305
Kerr JP, Liakopolou E, Brown J, Cornish, JM, Fleming, D, Massey, E, Oakhill, A, Pamphilon DH, Robinson SP, Totem A, Valencia AM, Marks DI (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 123:114–118
Kutko MC, Calarco MP, Flaherty MB, Helmrich RF, Ushay HM, Pon S, Greenwald BM (2003) Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med 4(3):333–337
Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B (2003) Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29(10):1688–1695
Lee JJ, Chung IJ, Park MR, Kook H, Hwang TJ, Ryang DW, Kim HJ (2001) Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia 15:203–207
Lehrnbecher T, Chanock SJ (1998) Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol 5:26–32
Liang DC (2003) The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatr Drugs 5:673–684
Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, Tuchschmid P, Willi UV, Ozsahin M, Crompton NE, Seger RA (1998) Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 92:2719–2724
Peters C, Minkov M, Matthes-Martin S, Potschger U, Witt V, Mann, G, Höcker, P, Worel N, Stary J, Klingebiel T, Gadner H (1999) Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 106:689–696
Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, Dale DC (2000) Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302–3309
Rossi C, Klastersky J (1996) Initial empirical antibiotic therapy for neutropenic fever:analysis of the causes of death. Support Care Cancer 4(3):207–212
Schneider DT, Lemburg P, Sprock I, Heying R, Gobel U, Nurnberger W (2000) Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children. Bone Marrow Transplant 25:1079–1086
Tomaske M, Bosk A, Eyrich M, Bader P, Niethammer D (2003) Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. Br J Haematol 121(6):886–891
van Burik JA, Weisdorf DJ (2002) Is it time for a new look at granulocyte transfusions? Transfusion 42:1393–1395